ArriVent BioPharma, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

ArriVent BioPharma, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$177.53M	-$94.31M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$166.31M	-$80.49M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-4.32	$-2.56
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-4.32	$-2.56

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$45.54M	$74.29M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$333.17M	$274.94M
Everything the company owes — debt, unpaid bills, and other obligations.	$25.95M	$17.29M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$307.22M	$257.65M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$160.59M	-$70.21M